Amgen Inc (HKSE:04332)
HK$ 1761 0 (0%) Market Cap: 1.17 Til Enterprise Value: 1.57 Til PE Ratio: 35.86 PB Ratio: 20.00 GF Score: 92/100

Amgen Inc at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 06:20PM GMT
Release Date Price: HK$1850
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning. Thanks, everyone, for joining us. I'm Salveen Richter, covered biotechnology at Goldman Sachs, and we're really pleased to have Bob Bradway, Chairman and CEO of Amgen with us. Bob, maybe to start here, a lot of big themes and events that are playing out in health care, especially specifically with relation to biopharma. Perhaps you could start by just talking about the recent FTC move to block your proposed acquisition of Horizon. What are your thoughts on the cross-bundling agreement? How do you expect this to play out? And what gives you confidence that this deal will still close?

Robert A. Bradway
Amgen Inc. - Chairman, CEO & President

Well, first, I'd say we remain very excited about the opportunity of combining with Horizon. So the more we've gotten to know the company and the opportunity, the more enthusiastic we've become about our ability to add value by combining forces with them. So I think in terms of our confidence in the law, we've been very clear, and I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot